FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2577884059> ?p ?o ?g. }

• W2577884059 abstract "Abstract Over the past decades, the use of optimized multi-agent chemotherapy protocols and improved risk stratification have led to superior patient outcome. However, avoiding therapy-related toxicity, decreasing the relapse rate of currently almost 20 % and improving the outcome of relapsed patients remain challenging problems. Aberrant activity of pathways involved in the regulation of survival and cell death contribute to development of leukemia and therapy failure. Anti-apoptotic BCL-2 family proteins are key regulators of apoptosis providing a promising target for novel directed therapies. The BH3 mimetic ABT-199 binds to BCL-2, counteracts its anti-death function and leads to apoptosis induction by direct release of pro-death BCL-2 family proteins such as BAX. BH3 mimetics are currently used pre-clinically and in first clinical trials. However the intrinsic or acquired resistance indicates the need for predictive markers and for effective combination treatment strategies. In this study, we addressed the activity of ABT-199 in B cell precursor (BCP) ALL. The effects of ABT-199 as single agent and in combination with chemotherapeutic drugs used in remission-induction therapy of pediatric ALL were analyzed using BCP-ALL cell lines (n=5) and a set of patient-derived primograft samples (n=9) established by transplantation of primary leukemia cells obtained from pediatric BCP-ALL patients at diagnosis onto immunodeficient NOD/SCID mice. Since ABT-199 does not bind to all antiapoptotic BCL-2 family members, sparing MCL-1, we included the cyclin-dependent kinase (CDK) inhibitor dinaciclib, which also exerts MCL-1 inhibitory effects. Cell viability was determined by flowcytometry according to fw/sc criteria and half maximal inhibitory concentrations (IC50) were estimated upon exposure to single agents and drug combinations. Combination indices (CI) indicating synergistic or additive effects were estimated according to Chou-Talalay. BCL-2 and MCL-1 protein levels were investigated by western blot analysis. Despite sensitivity in most of the BCP-ALL cell lines with IC50 values in the nanomolar range (mean IC50, 212 nM), one cell line, Nalm-6, showed ABT-199 resistance with an IC50 >10 µM. Interestingly, low protein levels of BCL-2 and increased MCL-1 expression were identified in this insensitive line, in contrast to high level BCL-2 and low MCL-1 expression in ABT-199 sensitive leukemias, indicating a potential marker to identify sensitive and resistant ALL. A pronounced synergism of ABT-199 in combination with chemotherapeutic agents was found with vincristine (CI 0.31 and 0.40, cell lines RS4;11 and Nalm-6) and even strong synergism with asparaginase and dexamethasone in ABT-199 monotherapy resistant Nalm-6 cells (CI 0.002, 0.14). Strikingly, the combination of the MCL-1 inhibitor dinaciclib with ABT-199 was highly effective and revealed a strong synergism for both compounds (CI 0.03). When we addressed the effects of ABT-199 on primograft ALL samples isolated from mice with full-blown leukemia, a pattern of high sensitivity (IC50 from 16 to 156 nM) similar to the cell lines was observed. In contrast, peripheral blood (PB) samples from healthy control donors were resistant to ex vivo exposure with ABT-199 (n=3, IC50 values > 1 µM). However, one primograft sample derived from a high risk patient showed ABT-199 insensitivity with an IC50 value of > 1 µM similar to healthy PBMCs. This primograft sample was also characterized by low BCL-2/high MCL-1 protein expression similar to Nalm-6. Most importantly, this resistant leukemia was also rendered ABT-199 sensitive by co-treatment with dinaciclib (CI 0.04). Taken together, we found efficacy of ABT-199 in the majority BCP-ALL cell lines and patient-derived primograft ALL samples and ABT-199 synergized with conventional chemotherapeutic agents. ABT-199 resistant leukemias characterized by low BCL-2/high MCL-1 expression were resensitized by addition of dinaciclib leading to strong synergism. These data indicate effective cell death sensitization by ABT-199 and potential strategies to overcome ABT-199 resistance in BCP-ALL. Disclosures No relevant conflicts of interest to declare." @default.
• W2577884059 created "2017-01-26" @default.
• W2577884059 creator A5015222907 @default.
• W2577884059 creator A5032561016 @default.
• W2577884059 creator A5057187390 @default.
• W2577884059 creator A5067061874 @default.
• W2577884059 date "2015-12-03" @default.
• W2577884059 modified "2023-09-28" @default.
• W2577884059 title "Synergistic Activity of ABT-199 with Conventional Chemotherapy and Dinaciclib in B-Cell Precursor Acute Lymphoblastic Leukemia" @default.
• W2577884059 doi "https://doi.org/10.1182/blood.v126.23.2631.2631" @default.
• W2577884059 hasPublicationYear "2015" @default.
• W2577884059 type Work @default.
• W2577884059 sameAs 2577884059 @default.
• W2577884059 citedByCount "1" @default.
• W2577884059 countsByYear W25778840592017 @default.
• W2577884059 crossrefType "journal-article" @default.
• W2577884059 hasAuthorship W2577884059A5015222907 @default.
• W2577884059 hasAuthorship W2577884059A5032561016 @default.
• W2577884059 hasAuthorship W2577884059A5057187390 @default.
• W2577884059 hasAuthorship W2577884059A5067061874 @default.
• W2577884059 hasConcept C121608353 @default.
• W2577884059 hasConcept C124320809 @default.
• W2577884059 hasConcept C126322002 @default.
• W2577884059 hasConcept C143998085 @default.
• W2577884059 hasConcept C190283241 @default.
• W2577884059 hasConcept C203014093 @default.
• W2577884059 hasConcept C2776694085 @default.
• W2577884059 hasConcept C2778461978 @default.
• W2577884059 hasConcept C2911091166 @default.
• W2577884059 hasConcept C29537977 @default.
• W2577884059 hasConcept C502942594 @default.
• W2577884059 hasConcept C55493867 @default.
• W2577884059 hasConcept C71924100 @default.
• W2577884059 hasConcept C86803240 @default.
• W2577884059 hasConcept C98274493 @default.
• W2577884059 hasConceptScore W2577884059C121608353 @default.
• W2577884059 hasConceptScore W2577884059C124320809 @default.
• W2577884059 hasConceptScore W2577884059C126322002 @default.
• W2577884059 hasConceptScore W2577884059C143998085 @default.
• W2577884059 hasConceptScore W2577884059C190283241 @default.
• W2577884059 hasConceptScore W2577884059C203014093 @default.
• W2577884059 hasConceptScore W2577884059C2776694085 @default.
• W2577884059 hasConceptScore W2577884059C2778461978 @default.
• W2577884059 hasConceptScore W2577884059C2911091166 @default.
• W2577884059 hasConceptScore W2577884059C29537977 @default.
• W2577884059 hasConceptScore W2577884059C502942594 @default.
• W2577884059 hasConceptScore W2577884059C55493867 @default.
• W2577884059 hasConceptScore W2577884059C71924100 @default.
• W2577884059 hasConceptScore W2577884059C86803240 @default.
• W2577884059 hasConceptScore W2577884059C98274493 @default.
• W2577884059 hasLocation W25778840591 @default.
• W2577884059 hasOpenAccess W2577884059 @default.
• W2577884059 hasPrimaryLocation W25778840591 @default.
• W2577884059 hasRelatedWork W1591903789 @default.
• W2577884059 hasRelatedWork W2031975865 @default.
• W2577884059 hasRelatedWork W2118863989 @default.
• W2577884059 hasRelatedWork W2269888391 @default.
• W2577884059 hasRelatedWork W2337923700 @default.
• W2577884059 hasRelatedWork W2338674998 @default.
• W2577884059 hasRelatedWork W2340300548 @default.
• W2577884059 hasRelatedWork W2342009840 @default.
• W2577884059 hasRelatedWork W2395292353 @default.
• W2577884059 hasRelatedWork W2417191938 @default.
• W2577884059 hasRelatedWork W2463716169 @default.
• W2577884059 hasRelatedWork W2550959716 @default.
• W2577884059 hasRelatedWork W2557672060 @default.
• W2577884059 hasRelatedWork W2566904807 @default.
• W2577884059 hasRelatedWork W2576782710 @default.
• W2577884059 hasRelatedWork W2585746906 @default.
• W2577884059 hasRelatedWork W2586567488 @default.
• W2577884059 hasRelatedWork W2980245895 @default.
• W2577884059 hasRelatedWork W65177702 @default.
• W2577884059 hasRelatedWork W68676002 @default.
• W2577884059 isParatext "false" @default.
• W2577884059 isRetracted "false" @default.
• W2577884059 magId "2577884059" @default.
• W2577884059 workType "article" @default.